| Autor: |
De Angel RE; College of Pharmacy, Pharmaceutics Division, University of Texas at Austin, Austin, TX, USA., Blando JM, Hogan MG, Sandoval MA, Lansakara-P DS, Dunlap SM, Hursting SD, Cui Z |
| Jazyk: |
angličtina |
| Zdroj: |
Cancer biology & therapy [Cancer Biol Ther] 2013 Apr; Vol. 14 (4), pp. 357-64. Date of Electronic Publication: 2013 Jan 28. |
| DOI: |
10.4161/cbt.23623 |
| Abstrakt: |
Obesity is associated with increased breast tumor aggressiveness and decreased response to multiple modalities of therapy in postmenopausal women. Delivering cancer chemotherapeutic drugs using nanoparticles has evolved as a promising approach to improve the efficacy of anticancer agents. However, the application of nanoparticles in cancer chemotherapy in the context of obesity has not been studied before. The nucleoside analog gemcitabine is widely used in solid tumor therapy. Previously, we developed a novel stearoyl gemcitabine solid-lipid nanoparticle formulation (GemC18-NPs) and showed that the GemC18-NPs are significantly more effective than gemcitabine in controlling tumor growth in mouse models. In the present study, using ovariectomized diet-induced obese female C57BL/6 mice with orthotopically transplanted MMTV-Wnt-1 mammary tumors as a model of postmenopausal obesity and breast cancer, we discovered that obesity induces tumor cell resistance to gemcitabine. Furthermore, our GemC18-NPs can overcome the obesity-related resistance to gemcitabine chemotherapy. These findings have important clinical implications for cancer chemotherapies involving gemcitabine or other nucleoside analogs in the context of obesity. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
